In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.
FOLFIRINOX is one of standard 1 st-line regimens for patients with advanced PDAC. However, there is no globally established 2 nd-line regimen after the failure of FOLFIRINOX. Although gemcitabine-based regimens are recommended by multiple guidelines and widely used in daily practice, further analysis is needed to reveal the magnitude of clinical benefit with these regimens. Nab-paclitaxel plus Gemcitabine (Nab-P+Gem) is another standard 1 st-line regimen for PDAC, but there are limited data as 2 nd-line therapy in PDAC. Therefore, the investigators are conducting a multicenter retrospective analysis of 2 nd-line nab-P+Gem after progression on FOLFIRINOX in patients with advanced PDAC.
Study Type
OBSERVATIONAL
Enrollment
103
Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
Asan Medical Center
Seoul, South Korea
Progression-free survival
Time from the start of 2nd-line nab-P + GEM to disease progression or death from any cause, whichever came first
Time frame: 1 year
Overall survival
Time from the start of 2nd-line nab-P+GEM to death from any cause
Time frame: 1 year
Objective response rates
Tumor response graded by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1
Time frame: 1 year
Toxicity profile
Safety profile graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.